For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Blueprint Medicines Corp (NASDAQ: BPMC) closed at $93.10 in the last session, up 0.11% from day before closing price of $93.00. In other words, the price has increased by $0.11 from its previous closing price. On the day, 0.62 million shares were traded. BPMC stock price reached its highest trading level at $94.86 during the session, while it also had its lowest trading level at $91.1162.
Ratios:
We take a closer look at BPMC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.66 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 5.93 whereas as Long-Term Debt/Eq ratio is at 5.30.
On August 21, 2023, Needham reiterated its Buy rating and also lowered its target price recommendation from $65 to $66.
Wells Fargo Upgraded its Equal Weight to Overweight on July 31, 2023, whereas the target price for the stock was revised from $55 to $82.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 28 ’24 when Landsittel Michael sold 5,000 shares for $95.00 per share. The transaction valued at 475,000 led to the insider holds 47,286 shares of the business.
Albers Jeffrey W. sold 25,073 shares of BPMC for $2,188,264 on Mar 20 ’24. The Director now owns 176,050 shares after completing the transaction at $87.28 per share. On Mar 15 ’24, another insider, Landsittel Michael, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 13,734 shares for $87.78 each. As a result, the insider received 1,205,606 and left with 47,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5848067072 and an Enterprise Value of 5764207616. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.86 while its Price-to-Book (P/B) ratio in mrq is 43.59. Its current Enterprise Value per Revenue stands at 23.114 whereas that against EBITDA is -12.145.
Stock Price History:
The Beta on a monthly basis for BPMC is 0.65, which has changed by 0.86610544 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, BPMC has reached a high of $101.00, while it has fallen to a 52-week low of $43.89. The 50-Day Moving Average of the stock is 2.71%, while the 200-Day Moving Average is calculated to be 32.34%.
Shares Statistics:
According to the various share statistics, BPMC traded on average about 805.71K shares per day over the past 3-months and 694710 shares per day over the past 10 days. A total of 61.15M shares are outstanding, with a floating share count of 59.80M. Insiders hold about 2.33% of the company’s shares, while institutions hold 106.12% stake in the company. Shares short for BPMC as of 1713139200 were 4245492 with a Short Ratio of 5.27, compared to 1710460800 on 5151094. Therefore, it implies a Short% of Shares Outstanding of 4245492 and a Short% of Float of 9.32.
Earnings Estimates
Blueprint Medicines Corp (BPMC) is presently subject to a detailed evaluation by 15.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$1.66 for the current quarter, with a high estimate of -$1.46 and a low estimate of -$1.8, while EPS last year was -$2.15. The consensus estimate for the next quarter is -$1.48, with high estimates of -$1.22 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.37 and -$6.28 for the fiscal current year, implying an average EPS of -$5.55. EPS for the following year is -$2.78, with 15.0 analysts recommending between -$0.27 and -$6.46.
Revenue Estimates
According to 15 analysts, the current quarter’s revenue is expected to be $80.41M. It ranges from a high estimate of $86.7M to a low estimate of $65M. As of the current estimate, Blueprint Medicines Corp’s year-ago sales were $63.29MFor the next quarter, 15 analysts are estimating revenue of $93.05M. There is a high estimate of $103M for the next quarter, whereas the lowest estimate is $87M.
A total of 16 analysts have provided revenue estimates for BPMC’s current fiscal year. The highest revenue estimate was $449M, while the lowest revenue estimate was $372M, resulting in an average revenue estimate of $393M. In the same quarter a year ago, actual revenue was $249.38MBased on 16 analysts’ estimates, the company’s revenue will be $596.03M in the next fiscal year. The high estimate is $738.9M and the low estimate is $481.18M.
